Cyrus is going to be very conservative in his comments so that the FDA doesn't start pouting. I however can use factual evidence from other studies to show what effect leronlimab will have. Let us hope the current leronlimab/checkpoint inhibitor study tracks PD-L1 inhibition and they publish those results.